You are here

Valchlor (Mechlorethamine) Antifungal Gel Launched in U.S.

First FDA-approved topical formulation of mechlorethamine (November 18)

Valchlor (Actelion Ltd.), the first FDA-approved topical formulation of mechlorethamine (commonly known as nitrogen mustard), is now available for patients in the U.S.

The gel, which is applied topically once a day, is an alkylating drug indicated to treat patients with stages IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) who have received prior skin-directed therapy.

Valchlor (mechlorethamine) gel 0.016% will be distributed in the U.S. by Accredo Specialty Pharmacy.

Mycosis fungoides is the most common type of cutaneous T-cell lymphoma, a rare form of non-Hodgkin's lymphoma. In the U.S., approximately 20,000 patients are currently diagnosed with stage IA-IB MF-CTCL, qualifying it as a rare or orphan disease.

Source: Actelion Ltd.; November 18, 2013.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function
U.S. maintains measles elimination status as NY outbreak ebbs
Study lists steps that could save close to $300 billion a year